Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Goldsite Diagnostics

Goldsite Diagnostics Inc. focuses on the development, manufacturing and sales of clinical laboratory devices and in-... read more Featured Products: More products

Download Mobile App




Portable POCT Immunofluorescence Analyzer Makes Testing Smarter, Faster and More Efficient

By LabMedica International staff writers
Posted on 12 May 2023
Print article
Image: The new FIA GO time-resolved immunofluorescence analyzer (Photo courtesy of Goldsite)
Image: The new FIA GO time-resolved immunofluorescence analyzer (Photo courtesy of Goldsite)

With existing POCT dry fluorescence methods it can be difficult to meet the accurate and sensitive detection requirements for clinical samples. The new time-resolved fluorescence immunoassay (TRFIA) technology uses time-resolved techniques to measure fluorescence, combines long decay lifetime markers with time-resolved fluorescence, effectively eliminating non-specific fluorescence interference and greatly improving analytical sensitivity. Now, a new time-resolved immunofluorescence analyzer uses TRFIA technology to quantitatively measure the concentration of analytes in blood or other samples at the POC.

The FIA Go from Goldsite Diagnostics Inc. (Shenzhen, China) is a compact fluorescent immunoassay analyzer designed for POCT settings. The rapid, quantitative instrument is based on TRFIA technology for high precision and low interference. The high-performance portable analyzer with a wide-ranging parameter menu provides professionals with high-quality medical information and user-friendly handling.

Featuring easy operation and an Android operating system, the FIA Go analyzer supports multiple tests, including Vitamin D, Ferritin, Folic acid, hormones, thyroid panels, etc. With its one-step operation, the FIA Go analyzer provides fast and accurate results in minutes at the POC, making it suitable for delivering timely primary care at the physician's office. Other flexible application scenarios include clinical laboratories, clinical departments, emergency outpatient clinics, and ambulances.

Related Links:
Goldsite Diagnostics 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.